Trial · NCT04790474
Ixazomib-pomalidomide-dexamethasone as Second or Third-line Combination Treatment for Patients With Relapsed and Refractory Multiple Myeloma Previously Treated With Daratumumab, Lenalidomide and Bortezomib
NCT04790474, Phase 2, Active not recruiting, Tel-Aviv Sourasky Medical Center
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Ixazomib-pomalidomide-dexamethasone as Second or Third-line Combination Treatment for Patients With Relapsed and Refractory Multiple Myeloma Previously Treated With Daratumumab, Lenalidomide and Bortezomib. Trials, record NCT04790474. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04790474
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
Ixazomib-pomalidomide-dexamethasone as Second or Third-line Combination Treatment for Patients With Relapsed and Refractory Multiple Myeloma Previously Treated With Daratumumab, Lenalidomide and Bortezomib
- NCT number
- NCT04790474
- Status
- Active not recruiting
- Phases
- Phase 2
- Enrollment
- 61 participants, actual
- Lead sponsor
- Tel-Aviv Sourasky Medical Center
- Conditions
- Multiple Myeloma in Relapse, Refractory Multiple Myeloma
- Interventions
- ixazomib-pomalidomide-dexamethasone
- First posted
- 2021-03-10
- Last updated
- 2026-08-11
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression-Free Survival-PFS | Up to 2 years from last patient enrollment | The time from first dose to the date of the first documented tumor progression or death due to any cause |
| Secondary | Objective Response Rate-ORR | Up to 2 years from last patient enrollment | Proportion of patients who achieve a best overall response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR), as defined using the IMWG criteria. |
| Secondary | Overall Survival-OS | Up to 2 years from last patient enrollment | The time between the date of first dose and the date of death due to any cause. OS will be censored on the last date a subject was known to be alive. |
| Secondary | Time To Response-TTR | Up to 2 years from last patient enrollment | The time from the first dose to the date of the first sCR, CR, VGPR, or PR. TTR will be evaluated for responders (BOR is either sCR, CR, VGPR, or PR) only. |
| Secondary | Duration of Response-DOR- | Up to 2 years from last patient enrollment | The time between the date of first response to the date of the first objectively documented tumor progression as assessed by study steering committee according to modified IMWG criteria or death due to any cause prior to subsequent anti-cancer therapy |
| Other | Optional Exploratory Analysis- RNA sequencing | Up to 2 years from last patient enrollment | RNA sequencing-by (Massively Parallel) MARS-seq method of fresh or frozen CD38+(cluster of differentiation 38)/CD138+ plasma cells (normal and malignant) in the bone marrow of patients |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 42719971 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04790474
GET https://conductscience.org/api/trials/v1/NCT04790474/registered